American Thoracic Society - Sanofi Investor Call
sanofi
Potential to lead in COPD with two biologics targeting
uncontrolled COPD in patients who failed standard of care
Patient population
G71 - 2035e
Non-Type 2
Type 2
DupixentⓇ and itepekimab have two distinct mechanisms of
action addressing different COPD populations with limited overlap
2023
2024
2025
Former
smokers
(70%)
Current
smokers
(30%)
itepekimab²
~1,139K patients
DupixentⓇ3
and
itepekimab²
~640K patients
Boreas
DUPIXENT
(dupilumab)
First-in-
disease
itepekimab
DupixentⓇ3
only
~270K patients
First-in-class
anti-IL-33
Notus
Aerify 1
Aerify 2
U.S. expected
submission
EU expected
submission
1. G7 countries: U.S., France, Germany, Italy, Japan, UK, Canada.
2. Itepekimab is under investigation and not yet approved by any regulatory agency. Itepekimab is being developed in collaboration with Regeneron. 3. Dupixent® is not yet approved
for COPD and is being studied in patients with uncontrolled COPD treated with current SoC triple therapy. Patient populations exclude never smokers.
35 ATS Investor CallView entire presentation